ArticleCirculation. Cardiovascular quality and outcomes2019
Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy.
Article in Circulation. Cardiovascular quality and outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It reports registered trial NCT00000620. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Systolic Blood Pressure Intervention Trial
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Relationship Between Phenotyping and Individualized Absolute Risk Differences in Sepsis: A Secondary Analysis of Two Approaches in Two Multicenter Trials.Critical care explorations · 2025Trial
- Conditional Treatment Effect Analysis of Two Infusion Rates for Fluid Challenges in Critically Ill Patients: A Secondary Analysis of Balanced Solution versus Saline in Intensive Care Study (BaSICS) Trial.Annals of the American Thoracic Society · 2023Trial
- Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.The Lancet. Digital health · 2022Trial
- Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.Journal of the American College of Cardiology · 2021Trial
- A novel digital twin strategy to examine the implications of randomized clinical trials for real-world populations.NPJ digital medicine · 2026Article
- CAUSALRLSTACK: adaptive balancing of deep representation and causal effect estimation with application to HIV-related health data.BioData mining · 2025Article
- Reformulating patient stratification for targeting interventions by accounting for severity of downstream outcomes resulting from disease onset: a case study in sepsis.Journal of the American Medical Informatics Association : JAMIA · 2025Observational
- Transforming Hypertension Diagnosis and Management in The Era of Artificial Intelligence: A 2023 National Heart, Lung, and Blood Institute (NHLBI) Workshop Report.Hypertension (Dallas, Tex. : 1979) · 2025Review
- Application of artificial intelligence in hypertension.Clinical hypertension · 2024Review
- Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review.Cureus · 2024Review
- Barriers and Facilitators of Medication Adherence in Hypertension Patients: A Meta-Integration of Qualitative Research.Journal of patient experience · 2024Article
- Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.medRxiv : the preprint server for health sciences · 2023Article
- Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults.American journal of hypertension · 2023Article
- Machine-learning-based high-benefit approach versus conventional high-risk approach in blood pressure management.International journal of epidemiology · 2023Article
- Methodological concerns about "concordance-statistic for benefit" as a measure of discrimination in predicting treatment benefit.Diagnostic and prognostic research · 2023Article
- Survey and Evaluation of Hypertension Machine Learning Research.Journal of the American Heart Association · 2023Article
- Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve.Journal of cardiovascular development and disease · 2023Review
- Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.Annals of epidemiology · 2022Article
- Teaching reproducible research for medical students and postgraduate pharmaceutical scientists.BMC research notes · 2021Article
Corrections and comments
- Retraction · 2023-09-26Error in Analyses · Error in Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe absolute risk reduction (ARR) in cardiovascular events from therapy is generally assumed to be proportional to baseline risk-such that high-risk patients benefit most. Yet newer analyses have proposed using randomized trial data to develop models that estimate individual treatment effects. We tested 2 hypotheses: first, that models of individual treatment effects would reveal that benefit from intensive blood pressure therapy is proportional to baseline risk; and second, that a machine learning approach designed to predict heterogeneous treatment effects-the X-learner meta-algorithm-is equivalent to a conventional logistic regression approach. METHODS AND
resultsWe compared conventional logistic regression to the X-learner approach for prediction of 3-year cardiovascular disease event risk reduction from intensive (target systolic blood pressure <120 mm Hg) versus standard (target <140 mm Hg) blood pressure treatment, using individual participant data from the SPRINT (Systolic Blood Pressure Intervention Trial; N=9361) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure; N=4733) trials. Each model incorporated 17 covariates, an indicator for treatment arm, and interaction terms between covariates and treatment. Logistic regression had lower C statistic for benefit than the X-learner (0.51 [95% CI, 0.49-0.53] versus 0.60 [95% CI, 0.58-0.63], respectively). Following the logistic regression's recommendation for individualized therapy produced restricted mean time until cardiovascular disease event of 1065.47 days (95% CI, 1061.04-1069.35), while following the X-learner's recommendation improved mean time until cardiovascular disease event to 1068.71 days (95% CI, 1065.42-1072.08). Calibration was worse for logistic regression; it over-estimated ARR attributable to intensive treatment (slope between predicted and observed ARR of 0.73 [95% CI, 0.30-1.14] versus 1.06 [95% CI, 0.74-1.32] for the X-learner, compared with the ideal of 1). Predicted ARRs using logistic regression were generally proportional to baseline pretreatment cardiovascular risk, whereas the X-learner observed-correctly-that individual treatment effects were often not proportional to baseline risk.
conclusionsPredictions for individual treatment effects from trial data reveal that patients may experience ARRs not simply proportional to baseline cardiovascular disease risk. Machine learning methods may improve discrimination and calibration of individualized treatment effect estimates from clinical trial data. CLINICAL
trial registrationURL: https://www.clinicaltrials.gov . Unique identifiers: NCT01206062; NCT00000620.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.